1035428-97-7

Basic information

• Product Name: N-[1-(4-dibenzo[b,f][1,4]thiazepin-11-yl-piperazin-1-yl)-ethyl]-2,2,2-trifluoroacetamide
• Synonyms: N-[1-(4-dibenzo[b,f][1,4]thiazepin-11-yl-piperazin-1-yl)-ethyl]-2,2,2-trifluoroacetamide
• CAS NO: 1035428-97-7
• Molecular Weight: 434.485
• Mol File: 1035428-97-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-[1-(4-dibenzo[b,f][1,4]thiazepin-11-yl-piperazin-1-yl)-ethyl]-2,2,2-trifluoroacetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[1-(4-dibenzo[b,f][1,4]thiazepin-11-yl-piperazin-1-yl)-ethyl]-2,2,2-trifluoroacetamide(1035428-97-7)
• EPA Substance Registry System: N-[1-(4-dibenzo[b,f][1,4]thiazepin-11-yl-piperazin-1-yl)-ethyl]-2,2,2-trifluoroacetamide(1035428-97-7)

Safety Data

• Hazardous Substances Data: 1035428-97-7(Hazardous Substances Data)

Upstream product

• 5747-48-8 11-(1-piperazinyl)dibenzo[b,f][1,4]thiazepine 
• 354-38-1 2,2,2-trifluoroacetamide 
• 75-07-0 acetaldehyde 

Relevant articles and documents

COMPOUNDS AND USES THEREOF

This invention relates to novel compounds having the structural Formula (I) below: and their pharmaceutically acceptable salts or tautomers, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of at least one symptom or condition associated with schizophrenia and other psychotic disorders, dementia and other cognitive disorders, anxiety disorders, mood disorders, sleep disorders, disorders usually first diagnosed in infancy, childhood, or adolescence and neurodegenerative disorders.